Lung Cancer Screening: Implementing Low-Dose CT in Your Practice

Lung cancer remains the leading cause of cancer death worldwide. Low-dose computed tomography (LDCT) screening has been shown to reduce lung cancer mortality by approximately 20% in high-risk populations, yet screening rates remain critically low — less than 6% of eligible individuals in the United States undergo screening.

Who Should Be Screened

The USPSTF recommends annual LDCT screening for adults aged 50-80 years who have a 20+ pack-year smoking history and currently smoke or have quit within the past 15 years. The NCCN and ATS guidelines align with these core criteria.

Implementing a Screening Program

Step 1: Identify Eligible Patients

Use EHR-based alerts, pack-year calculators, and targeted questioning during routine visits. Many eligible patients are seen in pulmonology clinics for other reasons — opportunistic screening discussions during any clinical encounter are valuable.

Step 2: Shared Decision Making

Discuss the benefits (20% mortality reduction demonstrated in NLST and NELSON trials), the potential harms (false positives leading to invasive procedures, cumulative radiation exposure, overdiagnosis), and the importance of annual adherence to screening.

Step 3: Follow the Lung-RADS System

The American College of Radiology's Lung-RADS classification standardizes nodule assessment and management recommendations, reducing variability in follow-up. Categories range from 1 (negative) to 4 (suspicious), with specific follow-up intervals for each.

Managing Incidental Findings

LDCT frequently identifies incidental findings — coronary artery calcification, emphysema, and pulmonary nodules. A structured reporting and follow-up system is essential to manage these findings appropriately.

Barriers and Solutions

Key barriers include lack of awareness among providers and patients, logistical challenges with scheduling and insurance prior authorization, and concerns about false positives. Solutions include clinic-based screening navigators, EHR-based clinical decision support, and patient education materials.

References: USPSTF Lung Cancer Screening Recommendation (2021); NLST and NELSON Trial Results; ACR Lung-RADS Assessment Categories.